Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 22/6/2017
SIETES contiene 91846 citas

 
 
 1 a 20 de 93 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Cowley NJ, Owen A, Shiels SC, Millar J, Woolley R, Ives N, Osman H, Moss P, Bion FJ. Safety and efficacy of antiviral therapy for prevention of cytomegalovirus reactivation in immunocompetent critically ill patients: a randomized clinical trial. JAMA Intern Med 2017;177:774-83. [Ref.ID 101617]
2. Cita con resumen
Anónimo. Finasteride: rare reports of depression and suicidal thoughts. Drug Safety Update 2017;10:2-3. [Ref.ID 101600]
4.Tiene citas relacionadas Cita con resumen
Berkovic SF. Cannabinoids for epilepsy — Real data, at last. N Engl J Med 2017;376:2075-6. [Ref.ID 101596]
5.Tiene citas relacionadas Cita con resumen
Devinsky O, Cross JH, Laux L, Marsh E, Nabbout R, Scheffer IE, Thiele EA, Wright S, for the Cannabidiol in Dravet Syndrome Study Group. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017;376:2011-20. [Ref.ID 101595]
6.Tiene citas relacionadas Cita con resumen
Curfman G. Risks of statin therapy in older adults. JAMA Intern Med 2017:22 de mayo. [Ref.ID 101591]
7.Tiene citas relacionadas Cita con resumen
Han BH, Sutin D, Williamson JD, Davis BR, Piller LB, Pervin H, Pressel SL, Blaum CS, for the ALLHAT Collaborative Research Group. Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults. The ALLHAT-LLT randomized clinical trial. JAMA Intern Med 2017:22 de mayo. [Ref.ID 101590]
8.Tiene citas relacionadas Cita con resumen
Shehab N, Lovegrove MC, Geller AI, Rose KO, Weidle NJ, Budnitz DS. US emergency department visits for outpatient adverse drug events, 2013-1014. JAMA 2016;316:2115-25. [Ref.ID 100973]
9. Cita con resumen
Anónimo. Various states approve recreational, medical marijuana use. DIA Daily 2016:7. [Ref.ID 100907]
10. Cita con resumen
Carvalho C, Machado Caetano J, Cunha L, Rebouta P, Kaptchuk TJ, Kirsch I. Open-label placebo treatment in chronic low back pain: a randomized controlled trial. Pain 2016:13 de octubre. [Ref.ID 100899]
12. Cita con resumen
Gargiulo G, Windecker S, da Costa BR, Feres F, Hong M-K, Gilard M, Kim H-S, Colombo A, Bhatt DL, Kim B-K, Morice M-C, Park KW, Chieffo A, Palmerini T, Stone GW, Valgimigli M. Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials. BMJ 2016;355:i5483. [Ref.ID 100878]
14. Cita con resumen
Anónimo. Gilead’s hepatitis C drug sales decline. DIA Daily 2016:11. [Ref.ID 100874]
17. Cita con resumen
Selvanderan SP, Summers MJ, Finnis ME, Plummer MP, Ali Abdelhamid Y, Anderson MB, Chapman MJ, Rayner CK, Deane AM. Pantoprazole or placebo for stress ulcer prophylaxis (POP-UP): randomized double-blind exploratory study. Crit Care Med 2016;44:1842-50. [Ref.ID 100852]
18. Cita con resumen
Anónimo. EMA releases clinical trial data in transparency effort. DIA Daily 2016:1. [Ref.ID 100849]
19. Cita con resumen
Graham DJ, Reichman ME, Wernecke M, Hsueh Y-H, Izem R, Southworth MR, Wei Y, Liao J, Goulding MR, Mott K, Chillarige Y, MaCurdy TE, Worrall C, Kelman JA. Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med 2016:3 de octubre. [Ref.ID 100779]
20. Cita con resumen
Anónimo. FDA approves appetite suppressant. DIA Daily 2016:2. [Ref.ID 100763]
Seleccionar todas
 
 1 a 20 de 93 siguiente >>